HRP20090618T1 - Uporaba peptida koji proizlaze iz b beta lanca humanog fibrinogena za liječenje šoka - Google Patents

Uporaba peptida koji proizlaze iz b beta lanca humanog fibrinogena za liječenje šoka Download PDF

Info

Publication number
HRP20090618T1
HRP20090618T1 HR20090618T HRP20090618T HRP20090618T1 HR P20090618 T1 HRP20090618 T1 HR P20090618T1 HR 20090618 T HR20090618 T HR 20090618T HR P20090618 T HRP20090618 T HR P20090618T HR P20090618 T1 HRP20090618 T1 HR P20090618T1
Authority
HR
Croatia
Prior art keywords
peptide
moiety
shock
denotes
chain
Prior art date
Application number
HR20090618T
Other languages
English (en)
Croatian (hr)
Inventor
Petzelbauer Peter
Zacharowski Kai
Original Assignee
Fibrex Medical Research & Development Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT0108704A external-priority patent/AT414097B/de
Priority claimed from AT0004005A external-priority patent/AT501263B1/de
Application filed by Fibrex Medical Research & Development Gmbh filed Critical Fibrex Medical Research & Development Gmbh
Publication of HRP20090618T1 publication Critical patent/HRP20090618T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20090618T 2004-06-25 2005-06-24 Uporaba peptida koji proizlaze iz b beta lanca humanog fibrinogena za liječenje šoka HRP20090618T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0108704A AT414097B (de) 2004-06-25 2004-06-25 Pharmazeutische zubereitung zur behandlung von schock
AT0004005A AT501263B1 (de) 2005-01-13 2005-01-13 Pharmazeutische zubereitung zur behandlung von schock
PCT/AT2005/000228 WO2006000007A1 (de) 2004-06-25 2005-06-24 Verwendung von peptiden, die aus der a alpha oder der b beta kette des humanen fibrinogens abgeleitet wurden, zur behandlung von schock

Publications (1)

Publication Number Publication Date
HRP20090618T1 true HRP20090618T1 (hr) 2010-01-31

Family

ID=35058593

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20090618T HRP20090618T1 (hr) 2004-06-25 2005-06-24 Uporaba peptida koji proizlaze iz b beta lanca humanog fibrinogena za liječenje šoka

Country Status (19)

Country Link
US (1) US20080249006A1 (pl)
EP (1) EP1691827B1 (pl)
JP (1) JP2008503503A (pl)
AT (1) ATE439856T1 (pl)
AU (1) AU2005256121B2 (pl)
BR (1) BRPI0506148A (pl)
CA (1) CA2544676A1 (pl)
CY (1) CY1109631T1 (pl)
DE (1) DE502005007926D1 (pl)
DK (1) DK1691827T3 (pl)
EA (1) EA008799B1 (pl)
ES (1) ES2331958T3 (pl)
HR (1) HRP20090618T1 (pl)
IL (1) IL173969A (pl)
NZ (1) NZ545634A (pl)
PL (1) PL1691827T3 (pl)
PT (1) PT1691827E (pl)
SI (1) SI1691827T1 (pl)
WO (1) WO2006000007A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT502987A1 (de) * 2005-12-23 2007-07-15 Fibrex Medical Res & Dev Gmbh Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen
WO2007095659A1 (de) * 2006-02-23 2007-08-30 Fibrex Medical Research & Development Gmbh Peptide und peptid-derivate, herstellun derselben sowie deren verwendung zur herstellung eines therapeutisch und/oder präventiv wirkenden arzneimittels
EP1987062B1 (en) * 2006-02-23 2011-06-22 Fibrex Medical Research & Development GmbH Peptides and peptide derivatives as well as pharmaceutical compositions containing the same
PL1987063T3 (pl) * 2006-02-23 2010-03-31 Fibrex Medical Res & Development Gmbh Peptydy i pochodne peptydów, ich wytwarzanie oraz ich zastosowanie do wytwarzania terapeutycznie i/lub profilaktycznie czynnej kompozycji farmaceutycznej
WO2009039542A2 (en) * 2007-09-24 2009-04-02 Fibrex Medical Research & Development Gmbh Methods of screening for compounds having anti- inflammatory activity and/or prevent / treat vascular leak
JP5410997B2 (ja) * 2008-01-31 2014-02-05 則行 川村 うつ病およびうつ状態のマーカーおよびそれを用いた検出・診断
US7884074B2 (en) 2008-05-15 2011-02-08 Ikaria Development Subsidiary Two, LLC Compounds and methods for prevention and/or treatment of inflammation using the same
US8088890B2 (en) * 2008-09-26 2012-01-03 Fibrex Medical Research & Development Gmbh Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
WO2010043444A2 (en) * 2008-10-15 2010-04-22 Fibrex Medical Research & Development Gmbh Pharmaceutical preparation for the treatment and/or prevention of ischemia/reperfusion injury and the sequels thereof
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
WO2019051102A2 (en) 2017-09-08 2019-03-14 Maverick Therapeutics, Inc. Constrained conditionally activated binding proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965107A (en) * 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
DE19729591A1 (de) * 1997-07-10 1999-02-11 Therasorb Medizinische Systeme Mittel zur Behandlung und/oder Prophylaxe von Mikrozirkulationsstörungen
SI1341819T1 (sl) * 2000-12-12 2006-10-31 Fibrex Medical Res & Dev Gmbh Uporaba fibrinskih/fibrinogenskih peptidov in proteinov za pripravo zdravila
EP1420778B1 (en) * 2001-03-06 2006-11-22 Dorian Bevec Use of mek inhibitors for treating virus induced hemorrhagic shock or fever
EP1987062B1 (en) * 2006-02-23 2011-06-22 Fibrex Medical Research & Development GmbH Peptides and peptide derivatives as well as pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
DK1691827T3 (da) 2009-12-14
US20080249006A1 (en) 2008-10-09
ATE439856T1 (de) 2009-09-15
PT1691827E (pt) 2009-11-23
EA200600561A1 (ru) 2006-08-25
WO2006000007A1 (de) 2006-01-05
EP1691827B1 (de) 2009-08-19
PL1691827T3 (pl) 2010-01-29
AU2005256121B2 (en) 2011-03-03
EA008799B1 (ru) 2007-08-31
AU2005256121A8 (en) 2008-08-21
IL173969A0 (en) 2006-07-05
BRPI0506148A (pt) 2006-10-24
CY1109631T1 (el) 2014-08-13
EP1691827A1 (de) 2006-08-23
HK1093308A1 (zh) 2007-03-02
AU2005256121A1 (en) 2006-04-27
IL173969A (en) 2011-06-30
SI1691827T1 (sl) 2010-01-29
NZ545634A (en) 2009-09-25
JP2008503503A (ja) 2008-02-07
ES2331958T3 (es) 2010-01-21
DE502005007926D1 (de) 2009-10-01
CA2544676A1 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
JP5384342B2 (ja) 癌のような変更された細胞遊走に関連する障害の治療のための薬理学的活性を有するペプチド
UA103154C2 (uk) Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його
CY1109631T1 (el) Χρησιμοποιηση πεπτιδιων, τα οποια εχουν παραχθει απο την αα- ή ββ-αλυσιδα του ανθρωπινου ινωδογονου, για τη θεραπεια σοκ
RU2011135755A (ru) Антибиотические пептиды
HRP20041108B1 (hr) Peptidi povezani sa tumorom koji se vežu na mhc molekule
HRP20140586T1 (hr) Peptidi za lijeäśenje beta-amiloidoze
JP6553706B2 (ja) 抗微生物ペプチドデンドリマー
JP2015534972A5 (pl)
MX2022002476A (es) Peptido q-er.
MX2022003057A (es) Nuevos peptidos.
JPH03503048A (ja) 心房の，ナトリウム排出亢進性ペプチドの直鎖アナログ
ATE455792T1 (de) Neues phosphatbindendes protein, pharmazeutische zusammensetzungen, die dieses enthalten, und verwendung davon
JPWO1997015598A1 (ja) 新規ペプチド
JPH02500517A (ja) ペプチド化合物
WO2020066343A1 (ja) 細胞膜透過性ペプチド
TW209171B (pl)
UA91497C2 (ru) ПРИМЕНЕНИЕ ПЕПТИДОВ, ВЫДЕЛЕННЫХ ИЗ ЦЕПИ Bb ЧЕЛОВЕЧЕСКОГО ФИБРИНОГЕНА, ДЛЯ ЛЕЧЕНИЯ ШОКА
EP3771719A8 (en) A peptide binding to tau-protein
ATE492637T1 (de) An die lck-sh3 und hck-sh3 domäne bindende peptide
Kim et al. Study on Application of the Colla corii Asini Blended Prescription from The Dongeuybogam
DE202015006574U1 (de) Peptid zur Beschichtung von Oberflächen
AU633128B2 (en) Anticoagulant peptides
NZ801728A (en) Atf5 peptide variants and uses thereof
Czyzewski Discerning the therapeutic potential of peptoid-based mimics of bioactive proteins
NZ801728B2 (en) ATF5 peptide variants and uses thereof